TipRanks
Jazz Pharmaceuticals (DE:J7Z)
XETRA:J7Z
Germany Market
J7Z
Jazz Pharmaceuticals
RESEARCH TOOLSreports

Jazz Pharmaceuticals (J7Z) Stock Forecast & Price Target

3 Followers
See the Price Targets and Ratings of:

J7Z Analyst Ratings

Strong Buy
19Ratings
Strong Buy
18 Buy
1 Hold
0 Sell
Based on 19 analysts giving stock ratings to
Jazz
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

J7Z Stock 12 Month Forecast

Average Price Target

€264.82
▲(23.17% Upside)
Based on 19 Wall Street analysts offering 12 month price targets for Jazz Pharmaceuticals in the last 3 months. The average price target is €264.82 with a high forecast of €300.17 and a low forecast of €203.97. The average price target represents a 23.17% change from the last price of €215.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"115":"€115","208":"€208","301":"€301","161.5":"€161.5","254.5":"€254.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":300.16575846,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€300.17</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":264.8190488115789,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€264.82</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":203.97020382,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€203.97</span>\n  </div></div>","useHTML":true}}],"tickPositions":[115,161.5,208,254.5,301],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,207.4,214.53582757384615,221.67165514769232,228.80748272153846,235.9433102953846,243.07913786923078,250.21496544307692,257.3507930169231,264.48662059076923,271.6224481646154,278.7582757384615,285.8941033123077,293.02993088615386,{"y":300.16575846,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,207.4,211.816849908583,216.23369981716598,220.650549725749,225.067399634332,229.48424954291497,233.90109945149797,238.31794936008095,242.73479926866395,247.15164917724695,251.56849908582993,255.98534899441293,260.4021989029959,{"y":264.8190488115789,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,207.4,207.13616952461538,206.87233904923076,206.60850857384617,206.34467809846154,206.08084762307692,205.8170171476923,205.5531866723077,205.28935619692308,205.02552572153846,204.76169524615383,204.49786477076924,204.23403429538462,{"y":203.97020382,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":116.45,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":119.1,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":147.6,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":142.8,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":141.5,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":163,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":162.55,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":172.35,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":199.1,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":218,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":219.6,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 54,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":210.1,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":207.4,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€300.17Average Price Target€264.82Lowest Price Target€203.97
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on DE:J7Z
Jason Gerberry
Bank of America Securities
Bank of America Securities
€273.44→€278.79
Buy
29.67%
Upside
Reiterated
10/09/26
Jazz Pharmaceuticals price target raised to $313 from $307 at BofAJazz Pharmaceuticals price target raised to $313 from $307 at BofA
RBC Capital Analyst forecast on DE:J7Z
Leonid Timashev
RBC Capital
RBC Capital
€266.32→€263.65
Buy
22.63%
Upside
Reiterated
10/08/26
Jazz Pharmaceuticals price target lowered to $296 from $299 at RBC CapitalJazz Pharmaceuticals price target lowered to $296 from $299 at RBC Capital
Truist Financial Analyst forecast on DE:J7Z
Gregory Renza
Truist Financial
Truist Financial
€250.29→€254.74
Buy
18.48%
Upside
Reiterated
10/07/26
Jazz Pharmaceuticals price target raised to $286 from $281 at TruistJazz Pharmaceuticals price target raised to $286 from $281 at Truist
Citi Analyst forecast on DE:J7Z
Geoff Meacham
Citi
Citi
€289.48
Buy
34.64%
Upside
Initiated
10/01/26
Jazz Pharmaceuticals initiated with a Buy at CitiJazz Pharmaceuticals initiated with a Buy at Citi
Piper Sandler Analyst forecast on DE:J7Z
David Amsellem
Piper Sandler
Piper Sandler
€276.12
Buy
28.43%
Upside
Reiterated
09/28/26
Analysts Are Bullish on These Healthcare Stocks: Legend Biotech (LEGN), Ocugen (OCGN)
Bernstein Analyst forecast on DE:J7Z
Jeffrey Walch
Bernstein
Bernstein
€203.97
Hold
-5.13%
Downside
Reiterated
09/25/26
Bernstein Reaffirms Their Hold Rating on Jazz Pharmaceuticals (JAZZ)
Goldman Sachs Analyst forecast on DE:J7Z
Andrea Newkirk
Goldman Sachs
Goldman Sachs
€300.17
Buy
39.61%
Upside
Initiated
09/24/26
Goldman Sachs Resumes Coverage with a Buy Rating on Jazz Pharmaceuticals (JAZZ)
UBS Analyst forecast on DE:J7Z
Ashwani Verma
UBS
UBS
€280.57→€300.17
Buy
39.61%
Upside
Assigned
09/14/26
Jazz Pharmaceuticals price target raised to $337 from $315 at UBSJazz Pharmaceuticals price target raised to $337 from $315 at UBS
Barclays Analyst forecast on DE:J7Z
Etzer Darout
Barclays
Barclays
€240.49→€241.38
Buy
12.27%
Upside
Reiterated
09/10/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Needham Analyst forecast on DE:J7Z
Ami Fadia
Needham
Needham
€276.12
Buy
28.43%
Upside
Reiterated
08/31/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
TD Cowen Analyst forecast on DE:J7Z
Joseph Thome
TD Cowen
TD Cowen
€267.21
Buy
24.28%
Upside
Reiterated
08/31/26
Analysts Are Bullish on These Healthcare Stocks: Crispr Therapeutics AG (CRSP), Jazz Pharmaceuticals (JAZZ)
Canaccord Genuity Analyst forecast on DE:J7Z
Gary Nachman
Canaccord Genuity
Canaccord Genuity
€267.21
Buy
24.28%
Upside
Reiterated
08/31/26
Jazz Pharmaceuticals: Ziihera’s Strong 1L GEA Profile Supports Reiterated Buy Rating and Unchanged $300 Price Target
Morgan Stanley Analyst forecast on DE:J7Z
Sean Laaman
Morgan Stanley
Morgan Stanley
€252.07→€286.81
Buy
33.40%
Upside
Assigned
08/26/26
Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (NASDAQ: JAZZ), Amneal Pharmaceuticals (NASDAQ: AMRX) and Climb Bio (NASDAQ: CLYM)
Deutsche Bank Analyst forecast on DE:J7Z
David Hoang
Deutsche Bank
Deutsche Bank
€255.63→€267.21
Buy
24.28%
Upside
Reiterated
08/26/26
Jazz Pharmaceuticals price target raised to $300 from $287 at Deutsche BankJazz Pharmaceuticals price target raised to $300 from $287 at Deutsche Bank
Wells Fargo Analyst forecast on DE:J7Z
Mohit Bansal
Wells Fargo
Wells Fargo
€267.21
Buy
24.28%
Upside
Reiterated
08/10/26
Wells Fargo Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on DE:J7Z
Jason Gerberry
Bank of America Securities
Bank of America Securities
€273.44→€278.79
Buy
29.67%
Upside
Reiterated
10/09/26
Jazz Pharmaceuticals price target raised to $313 from $307 at BofAJazz Pharmaceuticals price target raised to $313 from $307 at BofA
RBC Capital Analyst forecast on DE:J7Z
Leonid Timashev
RBC Capital
RBC Capital
€266.32→€263.65
Buy
22.63%
Upside
Reiterated
10/08/26
Jazz Pharmaceuticals price target lowered to $296 from $299 at RBC CapitalJazz Pharmaceuticals price target lowered to $296 from $299 at RBC Capital
Truist Financial Analyst forecast on DE:J7Z
Gregory Renza
Truist Financial
Truist Financial
€250.29→€254.74
Buy
18.48%
Upside
Reiterated
10/07/26
Jazz Pharmaceuticals price target raised to $286 from $281 at TruistJazz Pharmaceuticals price target raised to $286 from $281 at Truist
Citi Analyst forecast on DE:J7Z
Geoff Meacham
Citi
Citi
€289.48
Buy
34.64%
Upside
Initiated
10/01/26
Jazz Pharmaceuticals initiated with a Buy at CitiJazz Pharmaceuticals initiated with a Buy at Citi
Piper Sandler Analyst forecast on DE:J7Z
David Amsellem
Piper Sandler
Piper Sandler
€276.12
Buy
28.43%
Upside
Reiterated
09/28/26
Analysts Are Bullish on These Healthcare Stocks: Legend Biotech (LEGN), Ocugen (OCGN)
Bernstein Analyst forecast on DE:J7Z
Jeffrey Walch
Bernstein
Bernstein
€203.97
Hold
-5.13%
Downside
Reiterated
09/25/26
Bernstein Reaffirms Their Hold Rating on Jazz Pharmaceuticals (JAZZ)
Goldman Sachs Analyst forecast on DE:J7Z
Andrea Newkirk
Goldman Sachs
Goldman Sachs
€300.17
Buy
39.61%
Upside
Initiated
09/24/26
Goldman Sachs Resumes Coverage with a Buy Rating on Jazz Pharmaceuticals (JAZZ)
UBS Analyst forecast on DE:J7Z
Ashwani Verma
UBS
UBS
€280.57→€300.17
Buy
39.61%
Upside
Assigned
09/14/26
Jazz Pharmaceuticals price target raised to $337 from $315 at UBSJazz Pharmaceuticals price target raised to $337 from $315 at UBS
Barclays Analyst forecast on DE:J7Z
Etzer Darout
Barclays
Barclays
€240.49→€241.38
Buy
12.27%
Upside
Reiterated
09/10/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Needham Analyst forecast on DE:J7Z
Ami Fadia
Needham
Needham
€276.12
Buy
28.43%
Upside
Reiterated
08/31/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
TD Cowen Analyst forecast on DE:J7Z
Joseph Thome
TD Cowen
TD Cowen
€267.21
Buy
24.28%
Upside
Reiterated
08/31/26
Analysts Are Bullish on These Healthcare Stocks: Crispr Therapeutics AG (CRSP), Jazz Pharmaceuticals (JAZZ)
Canaccord Genuity Analyst forecast on DE:J7Z
Gary Nachman
Canaccord Genuity
Canaccord Genuity
€267.21
Buy
24.28%
Upside
Reiterated
08/31/26
Jazz Pharmaceuticals: Ziihera’s Strong 1L GEA Profile Supports Reiterated Buy Rating and Unchanged $300 Price Target
Morgan Stanley Analyst forecast on DE:J7Z
Sean Laaman
Morgan Stanley
Morgan Stanley
€252.07→€286.81
Buy
33.40%
Upside
Assigned
08/26/26
Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (NASDAQ: JAZZ), Amneal Pharmaceuticals (NASDAQ: AMRX) and Climb Bio (NASDAQ: CLYM)
Deutsche Bank Analyst forecast on DE:J7Z
David Hoang
Deutsche Bank
Deutsche Bank
€255.63→€267.21
Buy
24.28%
Upside
Reiterated
08/26/26
Jazz Pharmaceuticals price target raised to $300 from $287 at Deutsche BankJazz Pharmaceuticals price target raised to $300 from $287 at Deutsche Bank
Wells Fargo Analyst forecast on DE:J7Z
Mohit Bansal
Wells Fargo
Wells Fargo
€267.21
Buy
24.28%
Upside
Reiterated
08/10/26
Wells Fargo Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
MDWDMediwound
OVIDOvid Therapeutics
IMUXImmunic
ASNDAscendis Pharma
AORTArtivion
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Jazz Pharmaceuticals

3 Months
Joseph ThomeTD Cowen
Success Rate
13/21 ratings generated profit
62%
Average Return
+6.50%
Copying Joseph Thome's trades and holding each position for 3 Months would result in 61.90% of your transactions generating a profit, with an average return of +6.50% per trade.
1 Year
Joseph ThomeTD Cowen
Success Rate
18/21 ratings generated profit
86%
Average Return
+36.12%
Copying Joseph Thome's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +36.12% per trade.
2 Years
Joseph ThomeTD Cowen
Success Rate
19/21 ratings generated profit
90%
Average Return
+59.77%
Copying Joseph Thome's trades and holding each position for 2 Years would result in 90.48% of your transactions generating a profit, with an average return of +59.77% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

J7Z Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
0
0
0
0
0
Buy
31
35
54
50
44
Hold
4
4
2
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
35
39
56
51
45
In the current month, J7Z has received 44 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. J7Z average Analyst price target in the past 3 months is 264.82.
Each month's total comprises the sum of three months' worth of ratings.

J7Z Financial Forecast

J7Z Earnings Forecast

Next quarter’s earnings estimate for J7Z is €5.62 with a range of €5.12 to €6.20. The previous quarter’s EPS was €5.09. J7Z beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year J7Z has Performed in-line its overall industry.
Next quarter’s earnings estimate for J7Z is €5.62 with a range of €5.12 to €6.20. The previous quarter’s EPS was €5.09. J7Z beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year J7Z has Performed in-line its overall industry.

J7Z Sales Forecast

Next quarter’s sales forecast for J7Z is €1.07B with a range of €1.04B to €1.11B. The previous quarter’s sales results were €1.08B. J7Z beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year J7Z has Performed in-line its overall industry.
Next quarter’s sales forecast for J7Z is €1.07B with a range of €1.04B to €1.11B. The previous quarter’s sales results were €1.08B. J7Z beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year J7Z has Performed in-line its overall industry.

J7Z Stock Forecast FAQ

What is DE:J7Z’s average 12-month price target, according to analysts?
Based on analyst ratings, Jazz Pharmaceuticals’s 12-month average price target is 264.82.
    What is DE:J7Z’s upside potential, based on the analysts’ average price target?
    Jazz Pharmaceuticals has 23.17% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Jazz Pharmaceuticals a Buy, Sell or Hold?
          Jazz Pharmaceuticals has a consensus rating of Strong Buy, which is based on 18 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Jazz Pharmaceuticals’s share price target?
            The average share price target for Jazz Pharmaceuticals is 264.82. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €300.17 ,and the lowest forecast is €203.97. The average share price target represents 23.17% Increase from the current price of €215.
              What do analysts say about Jazz Pharmaceuticals?
              Jazz Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 19 Wall Streets Analysts.
                How can I buy shares of Jazz Pharmaceuticals?
                To buy shares of DE:J7Z, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.